|
¾Æµ¥ÄÚÄÚ¸®¾Æ |
RA & QC, QA Specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
03.01 |
|
|
ÅÛÇÁ½ºÅÜÄÚ¸®¾ÆÁÖ½Äȸ»ç |
[¿Ü±¹°è ÀÇ·á±â±â ±â¾÷] CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
02.27 |
|
|
(ÁÖ)ÀâÀ§µå |
[¿Ü±¹°èÁ¦¾à/»ï¼ºµ¿] CRA ä¿ë
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.03 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Global RA ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
01.07 |
|
|
(ÁÖ)¿¡ÄÚ½áÄ¡ |
Product Development Associate °æ·ÂÁ÷ Æ÷Áö¼Ç
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¶óÀ̼¾½ºIn/Out |
1³â¡è |
ä¿ë½Ã |
03.01 |
|
|
(ÁÖ)¸®¿ÂÆÄÆ®³Ê½º |
Country Head, Manager, Sr./Jr. cra ±Û·Î¹ú Pharm/cro(ÀçÅÃ
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.01 |
|
|
¸¶ÀϽºÅæ¼Ä¡ |
CRA¸¦ ã½À´Ï´Ù/Èñ±ÍÁúȯÀü¹® ±Û·Î¹ú ¿Ü±¹°èÁ¦¾àȸ»ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°£È£»ç |
1³â¡è |
ä¿ë½Ã |
06.19 |
|
|
(ÁÖ)ÄھƼġ |
Medical Advisor
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
˂ȍ |
½ÅÀÔ |
ä¿ë½Ã |
01.28 |
|
|
(ÁÖ)ÄھƼġ |
medical advisor
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.01 |
|
|
(ÁÖ)À¯ºñ¼Ò½Ã¾î½º |
[ÄÚ½ºÇÇ Á¦¾àȸ»ç] »ç¾÷°³¹ßÆÀ ½ÅÀÔ&°æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.20 |
|
|
(ÁÖ)ÇÇÇÃÄɾî½áÄ¡ |
¢º RA(Regulatory Affairs), ÀÇ·á±â±â ÇØ¿Ü ÀÎÇã°¡( RA)¾÷¹«
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.14 |
|
|
À̳ë¼Ä¡ |
ÇìµåÇåÅÍ Ãʺù
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÇìµåÇåÅÍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.19 |
|
|
(ÁÖ)ÀâÀ§µå |
[¿ÜÀÚÁ¦¾à/°³²¿ª] Àӻ󿬱¸ Coordinator(CRA)ä¿ë
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
°æ·Â¹«°ü |
ä¿ë½Ã |
09.22 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
Medical Science Liasion
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.02 |
|
|
ÄÚ¸®¾Æºê·¹ÀÎ ((ÁÖ)¿¡ÀÌÄ¡¾ËÇãºê) |
[¿Ü±¹°èÀÇ·á»ý¸í°øÇÐ] RA
¼¿ï ¿µµîÆ÷±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.14 |
|